Search results for abx831384

Erenumab, Abbexa, abx831384

Erenumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CALCRL/CGRP-R, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine.